Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 896.

https://doi.org/10.1182/blood-2024-197929

Published: 2024

Journal Articles

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards, Leyla O. Shune, Aimaz Afrough, Shonali Midha, Binod Dhakal, Mehmet H. Kocoglu, Shebli Atrash, Chris Ferreri, Omar Castaneda, James A Davis, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Laura B. Oswald, Gurbakhash Kaur, Oren Pasvolsky, Mahmoud R. Gaballa, Megan M Herr, Peter A. Forsberg, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Hamza Hashmi, Ran Reshef, Douglas W Sborov, Omar Nadeem, Faiz Anwer, Jack Khouri, Shahzad Raza, Djordje Atanackovic, Melissa Alsina, Ciara Louise Freeman, Frederick L. Locke, Peter M. Voorhees, Larry D Anderson, Jr., Shambavi Richard, Thomas Martin, Yi Lin, Krina K. Patel, Surbhi Sidana

Blood (2024) 144 (Supplement 1): 936.

https://doi.org/10.1182/blood-2024-194390

Published: 2024

Journal Articles

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility and Preliminary Outcomes from a Single-Arm Pilot Study

Nathan Parker, Morgan Bean, Mart Theodore De Vera, Rachel Carmella, Jessica McCoy, Salvatore Corallo, Luis Cuadrado Delgado, Meghan Menges, Omar Castaneda, Julio C. Chavez, Rawan Faramand, Michael D. Jain, Heather S.L. Jim, Aleksandr Lazaryan, Sayeef Mirza, Laura B. Oswald, Bijal D Shah, Frederick L. Locke, Ciara Louise Freeman

Blood (2024) 144 (Supplement 1): 7224.

https://doi.org/10.1182/blood-2024-208557

Published: 2024

Journal Articles

Trajectories of Patient-Reported Outcomes after Idecabtagene Vicleucel Vs. Ciltacabtagene Autoleucel CAR T-Cell Therapy Among Patients with Relapsed/Refractory Multiple Myeloma in Standard of Care

Blood (2024) 144 (Supplement 1): 7842.

https://doi.org/10.1182/blood-2024-208668

Published: 2024

Journal Articles

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Lauren C. Peres, Alicia Richards, Surbhi Sidana, Laura B. Oswald, Danai Dima, Aimaz Afrough, Leyla O. Shune, Shonali Midha, Omar Castaneda, Christopher Ferreri, James A Davis, Oren Pasvolsky, Christen M. Dillard, Megan M Herr, Mehmet H. Kocoglu, Shebli Atrash, Brandon Blue, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Mahmoud R. Gaballa, Peter A. Forsberg, Ciara Louise Freeman, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Djordje Atanackovic, Binod Dhakal, Jack Khouri, Shahzad Raza, Ran Reshef, Melissa Alsina, Frederick L. Locke, Omar Nadeem, Faiz Anwer, Larry D Anderson, Jr., Shambavi Richard, Yi Lin, Thomas Martin, Peter M. Voorhees, Krina K. Patel, Doris K. Hansen, Douglas W Sborov

Blood (2024) 144 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2024-210078

Published: 2024

Journal Articles

Meaningful Change in Patient-Reported Outcomes after CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma in Standard of Care: Differences By Race and Ethnicity

Blood (2024) 144 (Supplement 1): 5165.

https://doi.org/10.1182/blood-2024-208529

Published: 2024

Journal Articles

Sexual Health in Young Adult Patients after Chimeric Antigen Receptor T-Cell Therapy

Acadia Buro, Vivian Irizarry Gatell, Hayden J Fulton, Rebecca Blackwell, Kellie Zambrano, Yvelise Rodriguez, Xiaoyin Li, Xuefeng Wang, Laura B. Oswald, Rawan Faramand

Blood (2023) 142 (Supplement 1): 7378.

https://doi.org/10.1182/blood-2023-178242

Published: 2023

Journal Articles

A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Blood (2023) 142 (Supplement 1): 1004.

https://doi.org/10.1182/blood-2023-174506

Published: 2023

Journal Articles

Facility-Related Healthcare Resource Utilization (HCRU) for Patients Treated with Idecabtagene Vicleucel (Ide-Cel, bb2121) in a Real-World (RW) Setting: A Single-Center Experience

Blood (2023) 142 (Supplement 1): 5081.

https://doi.org/10.1182/blood-2023-173812

Published: 2023

Journal Articles

Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy

Blood (2022) 140 (Supplement 1): 623–625.

https://doi.org/10.1182/blood-2022-158478

Published: 2022

Journal Articles

Baseline Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Blood (2022) 140 (Supplement 1): 12778–12780.

https://doi.org/10.1182/blood-2022-158080

Published: 2022

Journal Articles

Associations between Patient-Reported Outcomes and 90-Day Response to Chimeric Antigen Receptor T-Cell Therapy: A Bayesian Network Analysis

Laura B. Oswald, Yi Luo, Xiaoyin Li, Aasha I. Hoogland, Brian D. Gonzalez, Doris K. Hansen, Michael D. Jain, Frederick L. Locke, Lauren C. Peres, Kedar Kirtane, Issam El Naqa, Heather S.L. Jim

Blood (2022) 140 (Supplement 1): 10913–10915.

https://doi.org/10.1182/blood-2022-169124

Published: 2022

Journal Articles

Change in Patients' Perceived Cognition Among Chimeric Antigen Receptor T-Cell Therapy Recipients at Day 360

Blood (2021) 138 (Supplement 1): 3052.

https://doi.org/10.1182/blood-2021-150838

Published: 2021

NARROW

Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility and Preliminary Outcomes from a Single-Arm Pilot Study

Trajectories of Patient-Reported Outcomes after Idecabtagene Vicleucel Vs. Ciltacabtagene Autoleucel CAR T-Cell Therapy Among Patients with Relapsed/Refractory Multiple Myeloma in Standard of Care

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Meaningful Change in Patient-Reported Outcomes after CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma in Standard of Care: Differences By Race and Ethnicity

Sexual Health in Young Adult Patients after Chimeric Antigen Receptor T-Cell Therapy

A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Facility-Related Healthcare Resource Utilization (HCRU) for Patients Treated with Idecabtagene Vicleucel (Ide-Cel, bb2121) in a Real-World (RW) Setting: A Single-Center Experience

Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy

Baseline Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Associations between Patient-Reported Outcomes and 90-Day Response to Chimeric Antigen Receptor T-Cell Therapy: A Bayesian Network Analysis

Change in Patients' Perceived Cognition Among Chimeric Antigen Receptor T-Cell Therapy Recipients at Day 360

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only